Influence of the Genetic Polymorphisms in the 5′ Flanking and Exonic Regions of CYP2C19 on Proguanil Oxidation

被引:12
作者
Satyanarayana, Chakradhara Rao Uppugunduri [1 ]
Devendran, Anichavezhi [1 ]
Jayaraman, Muthukumaran [3 ]
Mannu, Jayakanthan [3 ]
Mathur, Premendu P. [3 ]
Gopal, Shewade Deepak [1 ]
Rajagopal, Krishnamoorthy [2 ]
Chandrasekaran, Adithan [1 ]
机构
[1] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Pharmacol, Pharmacogenom Lab, Pondicherry 605006, India
[2] Hop Robert Debre, INSERM, U763, F-75019 Paris, France
[3] Pondicherry Univ, Ctr Bioinformat, Pondicherry, India
关键词
CYP2C19; promoter; transcription; variant alleles; transcription factor; phenotype; docking; South Indian; S-MEPHENYTOIN; 4-HYDROXYLATION; IN-VITRO; C/EBP-ALPHA; OMEPRAZOLE; METABOLISM; GENOTYPE; PHENOTYPE; ALLELES;
D O I
10.2133/dmpk.24.537
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP2C19 is a polymorphic enzyme which metabolizes several clinically important drugs including proguanil. Variation in the 5' regulatory region may influence CYP2C19 activity. This study evaluates the relationship between proguanil metabolic ratio and genetic variations of CYP2C19 in a South Indian population. Fifty unrelated healthy subjects were genotyped for CYP2C19 *2 and *3 alleles and the 5' flanking region of CYP2C19 was sequenced. Plasma concentrations of proguanil and cycloguanil were estimated by reverse phase HPLC after single oral doses (200 mg) of proguanil. In silico docking analysis of transcription factors binding to its sites in CYP2C19 5' regulatory region was performed. The mean metabolic ratios (proguanil/cycloguanil) were highest in *1/*2 or *1/*3 subjects and in *2/*2 or *2/*3 as compared to *1/*1 subjects. Subjects with promoter region variation -98T > C showed decrease in the metabolic ratios irrespective of other variation, which may explain the deviation from the genotype-phenotype association of CYP2C19. In silico analysis predicted alteration in the interaction of transcription factors to their binding sites in the presence of variant alleles. The results of this study would be useful in predicting interindividual differences in the metabolism of substrates of CYP2C19.
引用
收藏
页码:537 / 548
页数:12
相关论文
共 50 条
  • [31] Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
    Tu, J. -H.
    Hu, D. -L.
    Dai, L. -L.
    Sun, Y.
    Fan, L.
    Zhang, M.
    Tan, Z. -R.
    Chen, Y.
    Li, Z.
    Zhou, H. -H.
    XENOBIOTICA, 2010, 40 (06) : 393 - 399
  • [32] Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with prophylactic migraine treatment response
    Atasayar, Gulfer
    Eryilmaz, Isil Ezgi
    Karli, Necdet
    Egeli, Unal
    Zarifoglu, Mehmet
    Cecener, Gulsah
    Taskapilioglu, Ozlern
    Tunca, Berrin
    Yildirim, Oznur
    Ak, Secil
    Tezcan, Gulcin
    Can, Fatma Ezgi
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 366 : 149 - 154
  • [33] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients
    Kesavan, Ramasamy
    Narayan, Sunil K.
    Adithan, Chandrasekaran
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (07) : 689 - 696
  • [34] Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors
    Zhu, Liqin
    Liao, Shasha
    Wang, Nan
    Ge, Tingyue
    Yang, Jianwei
    Xu, Gaoqi
    Wang, Jianhai
    Li, Keqiu
    Li, Guang
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (08) : 587 - 596
  • [35] CYP3A4 and CYP2C19 genetic polymorphisms and myricetin interaction on tofacitinib metabolism
    Ye, Zhize
    Xia, Hailun
    Hu, Jinyu
    Liu, Ya-nan
    Wang, Anzhou
    Cai, Jian-ping
    Hu, Guo-xin
    Xu, Ren-ai
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 175
  • [36] Association of CYP2C19*2 and*17 genetic variants with hypertension in Pakistani population
    Riaz, Sana
    Mansoor, Atika
    Siddiqi, Saima
    Tareen, Muhammad Usman
    Rubab, Sana
    Batool, Ayesha
    Anwarullah
    Sultan, Aneesa
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2019, 18 (04) : 851 - 855
  • [37] Correlation of CYP2C19 Genetic Polymorphisms With Helicobacter pylori Eradication in Patients With Cirrhosis and Peptic Ulcer
    Lay, Chii-Shyan
    Lin, Jiun-Rong
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2010, 73 (04) : 188 - 193
  • [38] Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype
    Helsby, Nuala A.
    Lo, Wing-Yee
    Simpson, Ian J.
    Voss, David M.
    Logan, Kaye E.
    Searle, Martin
    Schollum, John B. W.
    de Zoysa, Janak R.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (05) : 516 - 519
  • [39] Association Study of Esomeprazole Pharmacokinetics and CYP2C19 Gene Polymorphisms
    Fang, Yuan
    He, Xia
    Peng, Ai
    Yang, Yi Qi
    Xiang, Jin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (02): : 134 - 139
  • [40] Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy
    Ahn, Seon-Jae
    Oh, Jaeseong
    Kim, Do-Yong
    Son, Hyoshin
    Hwang, Sungeun
    Shin, Hye-Rim
    Kim, Eun Young
    Lee, Han Sang
    Lee, Woo-Jin
    Moon, Jangsup
    Lee, Soon-Tae
    Jung, Keun-Hwa
    Park, Kyung-Il
    Jung, Ki-Young
    Lee, SeungHwan
    Yu, Kyung-Sang
    Chu, Kon
    Lee, Sang Kun
    EPILEPSIA, 2022, 63 (11) : 2958 - 2969